CELC Celcuity Inc.
Price Chart
Executive Summary
Celcuity priced a $500M upsized convertible senior notes offering (0.250% coupon, due 2032), increased from $400M, with an underwriter option for an additional $75M. Net proceeds of ~$484.3M (or ~$557M with over-allotment) will repay Oxford Finance debt and fund working capital, including clinical trials and potential commercialization. The conversion premium of ~40% above the last sale price signals moderate dilution risk, but the large capital raise provides a multi-year cash runway for a pre-revenue biotech awaiting FDA action on gedatolisib.
Key Financial Metrics
Actionable Insight
The $500M convertible offering significantly extends Celcuity's cash runway through potential FDA approval and commercialization of gedatolisib, but introduces dilution risk at a ~40% premium. Monitor the June 8 closing and any subsequent updates on the NDA review (PDUFA date not stated). Given the negative historical T+20 performance on CELC reports and the mixed nature of this event (capital infusion vs. dilution), traders should watch for near-term volatility around the offering close and potential overhang from the conversion option.
Key Facts
- Upsized convertible notes offering: $500M aggregate principal, increased from $400M.
- 0.250% coupon, maturing August 1, 2032; semi-annual interest payments.
- Initial conversion price ~$124.53 per share, ~40% premium above last reported sale price on June 3, 2026.
- Underwriters have 30-day option to purchase up to an additional $75M in notes for over-allotments.
- Net proceeds estimated at ~$484.3M (or ~$557M if over-allotment exercised in full).
- Proceeds to repay all outstanding obligations under Oxford Finance loan agreement; remainder for working capital, clinical trials, and potential commercialization.
- Offering expected to close June 8, 2026, subject to customary conditions.
- Company is clinical-stage, pre-revenue, with lead candidate gedatolisib in Phase 3 for HR+/HER2- breast cancer.
- Conversion premium of 40% provides some cushion against near-term dilution, but full conversion at $124.53 would add significant share count.
- Historical performance on CELC reports shows negative average returns at T+20 (-2.23%) and low win rate (33%), suggesting caution.
Financial Impact
Net proceeds of ~$484.3M (or ~$557M with over-allotment) provide substantial capital for a pre-revenue biotech with ~$4.3B market cap. Full conversion at $124.53 would add ~4.0M shares (based on $500M / $124.53), representing roughly 5-6% dilution relative to current shares outstanding (estimated from market cap and stock price). The 0.250% coupon is minimal interest expense.
Risk Factors
- Dilution risk: Full conversion of notes at $124.53 would add ~4M shares, potentially pressuring stock price.
- Execution risk: Proceeds used for clinical trials and commercialization; failure of gedatolisib to gain FDA approval would leave company with high cash burn and no revenue.
- Market risk: Convertible notes may create overhang if stock trades near conversion price, encouraging arbitrage activity.
- Historical calibration: Past CELC reports show negative average T+20 returns (-2.23%) and low win rate (33%), suggesting the market may react negatively to this capital raise despite the cash infusion.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306482 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $89.78 awaiting T+1 | awaiting T+1 | — | $88.55 (−1.37%) |
|
Jun 8, 2026
4d ago
|
8-K
| $87.39 awaiting T+1 | awaiting T+1 | — | $88.55 (+1.33%) |
|
Jun 5, 2026
8d ago
|
424B5
| $92.47 awaiting T+1 | awaiting T+1 | — | $88.55 (−4.24%) |
|
Jun 4, 2026
9d ago
|
Press Release
| $92.47 $88.28 | ▼ −4.53% | ▼ −1.93% | $88.55 (−4.24%) |
|
Jun 3, 2026
9d ago
|
Press Release
| $88.95 $92.47 | ▼ −3.96% | ▼ −3.56% | $88.55 (+0.45%) |
|
Jun 3, 2026
9d ago
|
424B5
| $88.95 $92.47 | ▼ −3.96% | ▼ −3.56% | $88.55 (+0.45%) |
|
Jun 2, 2026
10d ago
|
8-K
| $91.42 $88.95 | ▼ −2.70% | ▼ −2.01% | $88.55 (−3.14%) |
|
May 14, 2026
29d ago
|
Press Release
| $137.68 $132.18 | ▼ −3.99% | ▼ −3.93% | $88.55 (−35.68%) |
|
May 7, 2026
5w ago
|
Press Release
| $130.71 $131.06 | ▲ +0.27% | ▼ −0.56% | $88.55 (−32.25%) |
|
May 4, 2026
5w ago
|
144
| $144.98 $141.69 | ▼ −2.27% | ▼ −3.06% | $88.55 (−38.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access